Behind "AIDS breakthrough" headlines, December 2004: important research, not so new.
The mid-December press reports about an AIDS drug breakthrough were exaggerated, but the research described is important. It concerns the development of a class of related experimental drugs that work like efavirenz or nevirapine, but appear to be more powerful and much less subject to resistance.
James
John S
JS
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D006801:Humans; D009570:Nitriles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011724:Pyridazines / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000068696:Rilpivirine; D014481:United States
D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine; D000068696:Rilpivirine